Skip to main content

Blood Ketone Meter

A blood ketone meter is a handheld device that estimates beta-hydroxybutyrate (BHB) from a finger-prick capillary blood sample. Some combination meters measure glucose and BHB with different test strips.

Why clinicians prefer blood BHB for suspected DKA

BHB is the principal circulating ketoacid in diabetic ketoacidosis (DKA). Common urine strips measure acetoacetate instead. The 2024 international consensus recommends direct venous or capillary BHB measurement for DKA assessment and monitoring when available because urine acetoacetate can lag early in DKA and remain elevated during recovery.1

This does not make a home meter a stand-alone DKA test. The current diagnosis requires all three of the following:1

  • diabetes or glucose at least 200 mg/dL (11.1 mmol/L);
  • BHB at least 3.0 mmol/L or urine ketones at least 2+; and
  • venous pH below 7.3 and/or bicarbonate below 18 mmol/L.

A meter cannot assess pH, bicarbonate, dehydration, or the cause of an abnormal result. Euglycemic DKA can also occur below 200 mg/dL glucose, so a normal-looking glucose result does not rule it out.

Who may need a meter?

People at risk of DKA, especially those with type 1 diabetes, a previous DKA episode, pancreatic insulin deficiency, or an insulin pump, may be given a blood-ketone sick-day plan by their diabetes team. The plan should specify when to test, when to repeat a result, whom to call, and when to seek emergency care.

SGLT2 inhibitors are a separate high-risk context. The FDA warns that associated ketoacidosis can occur without very high glucose. Compatible symptoms during SGLT2-inhibitor use require immediate medical assessment regardless of the glucose reading.2

Routine testing is generally unnecessary for a ketogenic diet used outside a clinician-directed therapeutic program. A higher BHB number does not prove greater fat loss, better diet quality, or better health.

Using and interpreting a home result

Follow the meter and strip instructions exactly. Wash and dry hands, confirm the strips are compatible and unexpired, and note error messages. If a result is unexpected, repeat it only as the device instructions or clinical plan advise. Do not delay care while repeatedly testing.

Seek emergency care now for persistent vomiting, severe abdominal pain, deep or difficult breathing, confusion, fainting, or marked drowsiness. These signs are especially concerning for DKA with known or possible diabetes, pregnancy, or SGLT2-inhibitor use; do not wait for very high glucose. A home reading cannot establish that these symptoms are harmless.

Compared with ketone urine strips, blood testing reflects current circulating BHB more directly. Neither method should be used to optimize a general-diet “target.” See ketoacidosis (DKA) and the detailed ketosis-versus-DKA guide for clinical context.

Frequently Asked Questions

Can a blood ketone meter diagnose DKA?
No. It can measure the ketone component, but DKA also requires metabolic acidosis and diabetes or qualifying hyperglycemia. Home meters do not measure pH or bicarbonate.
Is blood BHB more useful than urine ketones for suspected DKA?
Yes, when available. The 2024 consensus prefers direct blood BHB because urine acetoacetate can underestimate ketonemia early and overestimate it during recovery.
Does normal glucose rule out DKA?
No. Euglycemic DKA occurs with glucose below 200 mg/dL and is associated with SGLT2 inhibitors, pregnancy, reduced food intake, alcohol-related impaired gluconeogenesis, liver failure, and insulin already taken before testing.
Should I test BHB every day on keto?
Routine testing is generally unnecessary for a ketogenic diet used outside an individualized diabetes plan or clinician-directed therapeutic program.

See also: BHB · Ketosis · Ketoacidosis (DKA) · Urine ketone strips · Detailed ketosis vs DKA guide · Full glossary

Works cited

  1. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report — Umpierrez GE, Davis GM, ElSayed NA, et al., Diabetes Care. 2024;47(8):1257–1275, doi:10.2337/dci24-0032August 23, 2026 https://pmc.ncbi.nlm.nih.gov/articles/PMC11272983/
  2. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections — U.S. Food and Drug Administration, revised March 15, 2022August 23, 2026 https://www.fda.gov/files/drugs/published/FDA-revises-labels-of-SGLT2-inhibitors-for-diabetes-to-include-warnings-about-too-much-acid-in-the-blood-and-serious-urinary-tract-infections.pdf

Article history

  1. Updated
  2. First published

Your learning guide

Loading reading status…